Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 7, 2024

https://www.globenewswire.com/news-release/2024/05/07/2877176/37216/en/Aclaris-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html

– Progressing ATI-2138 into Atopic Dermatitis –
– Management to Host Conference Call at 5:00 PM ET Today –

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.